Newton, MA (PRWEB) December 05, 2012
Topokine Therapeutics has announced that the first subject has been dosed in a repeat-dose, healthy volunteer study of XAF5 Gel, a skin cream for local reduction of excess subcutaneous fat (lipohypertrophy). The study is assessing the safety and tolerability of repeat doses of XAF5 Gel at three concentrations. The study is also quantifying the effects of XAF5 on subcutaneous adipose tissue.
“We are excited to enter clinical development with the first non-invasive, local drug therapy to reduce lipohypertrophy,” said Topokine’s Chief Scientific Officer, Michael Singer, MD, PhD. “We hope to provide a convenient and effective alternative to surgery and injections.”
XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.
“Topokine’s preclinical data are promising,” said Jeffrey S. Dover, MD, FRCPC, a nationally recognized dermatologist and member of the Company’s Scientific Board of Advisors. “A skin cream that reduces subcutaneous fat would be an attractive proposition for patients and physicians alike.”
The company expects to report top-line results in the first half of 2013.
About Topokine and XAF5 Gel
Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat. XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.
This press release contains forward-looking statements regarding the development of XAF5. These statements are based on Topokine’s current beliefs and expectations, but actual results may differ.
Read the full story at http://www.prweb.com/releases/2012/12/prweb10203404.htm.
Copyright©2012 Vocus, Inc.
All rights reserved